Lonza Group Ltd LZAGF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LZAGF is a good fit for your portfolio.
News
-
Lonza Shares Rise After Company Backs Outlook
-
Lonza Backs View Despite Earnings Slip
-
Lonza Backs Guidance Despite Soft Start to Year
-
NeuroSense Announces First Quarter 2024 Business Update
-
Lonza Finance Launches EUR1 Billion 12-Year Euro Bond
-
Lonza Taps Siegfried Holding's Wolfgang Wienand as Next CEO
-
Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche
-
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion
Trading Information
- Previous Close Price
- $633.00
- Day Range
- $650.00–678.80
- 52-Week Range
- $336.03–678.80
- Bid/Ask
- $566.81 / $719.83
- Market Cap
- $48.95 Bil
- Volume/Avg
- 89 / 126
Key Statistics
- Price/Earnings (Normalized)
- 37.38
- Price/Sales
- 6.51
- Dividend Yield (Trailing)
- 0.65%
- Dividend Yield (Forward)
- 0.65%
- Total Yield
- 3.42%
Company Profile
Lonza Group ltd is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Large Growth
- Total Number of Employees
- 17,834
- Website
- https://www.lonza.com
Competitors
Valuation
|
Metric
|
LZAGF
|
CTLT
|
02269
|
|---|---|---|---|
Price/Earnings (Normalized) | 37.38 | 103.02 | 11.45 |
Price/Book Value | 4.71 | 2.94 | 1.08 |
Price/Sales | 6.51 | 2.58 | 2.44 |
Price/Cash Flow | 32.72 | 43.71 | 7.76 |
Price/Earnings
LZAGF
CTLT
02269
Financial Strength
|
Metric
|
LZAGF
|
CTLT
|
02269
|
|---|---|---|---|
Quick Ratio | 1.38 | 1.56 | 2.35 |
Current Ratio | 2.04 | 2.51 | 2.78 |
Interest Coverage | 6.88 | −4.07 | 25.95 |
Quick Ratio
LZAGF
CTLT
02269
Profitability
|
Metric
|
LZAGF
|
CTLT
|
02269
|
|---|---|---|---|
Return on Assets (Normalized) | 5.18% | −3.09% | 8.91% |
Return on Equity (Normalized) | 9.32% | −7.79% | 13.28% |
Return on Invested Capital (Normalized) | 7.38% | −0.96% | 10.45% |
Return on Assets
LZAGF
CTLT
02269
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Gbsvyjhtwy | Rpc | $231.8 Bil | |||
| Danaher Corp
DHR
| Rssscxkb | Qzbnc | $197.8 Bil | |||
| IQVIA Holdings Inc
IQV
| Sltnzxjvd | Klhhffc | $43.7 Bil | |||
| Agilent Technologies Inc
A
| Tlrsppswwn | Qjfmq | $40.1 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Yqlvrjwprk | Wvjfbb | $38.8 Bil | |||
| Mettler-Toledo International Inc
MTD
| Mllrbdknw | Mvcwzg | $31.0 Bil | |||
| Icon PLC
ICLR
| Vdcgtytp | Njtlttg | $26.8 Bil | |||
| Illumina Inc
ILMN
| Dfpbywj | Dgjqx | $19.2 Bil | |||
| Waters Corp
WAT
| Qwfypyqqpc | Gsnxf | $18.9 Bil | |||
| Labcorp Holdings Inc
LH
| Sdgqrzjbvl | Qgvnpz | $17.8 Bil |